References
- Auffret, M., Drapier, S., & Vérin, M. (2018). The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future. Drugs in R&D, 18(2), 91–107. https://doi.org/10.1007/s40268-018-0230-3
- Bhattacharjee S. (2018). Impulse control disorders in Parkinson’s disease: Review of pathophysiology, epidemiology, clinical features, management, and future challenges. Neurology India, 66(4), 967–975. https://doi.org/10.4103/0028-3886.237019
- Evans, A. H., Okai, D., Weintraub, D., Lim, S. Y., O’Sullivan, S. S., Voon, V., Krack, P., Sampaio, C., Post, B., Leentjens, A. F. G., Martinez-Martin, P., Stebbins, G. T., Goetz, C. G., Schrag, A., & Members of the International Parkinson and Movement Disorder Society (IPMDS) Rating Scales Review Committee (2019). Scales to assess impulsive and compulsive behaviors in Parkinson’s disease: Critique and recommendations. Movement disorders : official journal of the Movement Disorder Society, 34(6), 791–798. https://doi.org/10.1002/mds.27689
- Katzenschlager, R., Poewe, W., Rascol, O., Trenkwalder, C., Deuschl, G., Chaudhuri, K. R., Henriksen, T., van Laar, T., Spivey, K., Vel, S., Staines, H., & Lees, A. (2018). Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. Neurology, 17(9), 749–759. https://doi.org/10.1016/S1474-4422(18) 30239-4
- Martinez-Martin, P., Reddy, P., Katzenschlager, R., Antonini, A., Todorova, A., Odin, P., Henriksen, T., Martin, A., Calandrella, D., Rizos, A., Bryndum, N., Glad, A., Dafsari, H. S., Timmermann, L., Ebersbach, G., Kramberger, M. G., Samuel, M., Wenzel, K., Tomantschger, V., Storch, A., … Chaudhuri, K. R. (2015). EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Movement disorders : official journal of the Movement Disorder Society, 30(4), 510–516. https://doi.org/10.1002/mds.26067
- Poewe, W., & Wenning, G. K. (2000). Apomorphine: an underutilized therapy for Parkinson’s disease. Movement disorders : official journal of the Movement Disorder Society, 15 (5), 789–794. https://doi.org/10.1002/1531-8257(200009)15:5<;789::aid-mds1005>3.0.co;2-h
- Prakash, N., & Simuni, T. (2020). Infusion Therapies for Parkinson’s Disease. Current neurology and neuroscience reports, 20(9), 44. https://doi.org/10.1007/s11910-020-01062-2
- Todorova, A., Samuel, M., Brown, R. G., & Chaudhuri, K. R. (2015). Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease: Clinical Experience After 3 Years’ Follow-up. Clinical neuropharmacology, 38(4), 132–134. https://doi.org/10.1097/WNF.0000000000000091
- Weintraub, D., & Claassen, D. O. (2017). Impulse Control and Related Disorders in Parkinson’s Disease. International review of neurobiology, 133, 679–717. https://doi.org/10.1016/bs.irn.2017.04.006
- Weintraub, D., & Nirenberg, M. J. (2013). Impulse control and related disorders in Parkinson’s disease. Neuro-degenerative diseases, 11(2), 63–71. https://doi.org/10.1159/000341996